Invesco Ltd. Has $278,000 Stock Holdings in Sana Biotechnology, Inc. $SANA

Key Points

• Invesco Ltd. increased its holdings in Sana Biotechnology by 241.5%, acquiring an additional 117,144 shares during the first quarter, now owning a total of 165,646 shares.
• Analysts remain optimistic about the stock, with a consensus rating of "Buy" and an average target price of $8.00, indicating potential growth.
• Despite the positive outlook, Sana Biotechnology's stock recently dipped by 0.7%, opening at $2.96, well below its 52-week high of $7.30.

Invesco Ltd. raised its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 241.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 165,646 shares of the company's stock after buying an additional 117,144 shares during the period. Invesco Ltd. owned about 0.07% of Sana Biotechnology worth $278,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of SANA. Tower Research Capital LLC TRC raised its stake in Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after buying an additional 10,548 shares during the period. Ameriprise Financial Inc. bought a new stake in Sana Biotechnology in the fourth quarter valued at approximately $29,000. Pallas Capital Advisors LLC bought a new stake in Sana Biotechnology in the first quarter valued at approximately $29,000. BNP Paribas Financial Markets bought a new stake in Sana Biotechnology in the fourth quarter valued at approximately $34,000. Finally, Focus Partners Wealth bought a new stake in Sana Biotechnology in the fourth quarter valued at approximately $35,000. Institutional investors own 88.23% of the company's stock.

Sana Biotechnology Price Performance

Sana Biotechnology stock traded down $0.18 during mid-day trading on Friday, reaching $3.22. 3,000,261 shares of the company were exchanged, compared to its average volume of 4,056,273. The company has a fifty day simple moving average of $3.72 and a 200-day simple moving average of $2.71. Sana Biotechnology, Inc. has a 12 month low of $1.26 and a 12 month high of $7.30. The firm has a market cap of $765.75 million, a PE ratio of -3.04 and a beta of 1.88.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. Sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Analysts Set New Price Targets

SANA has been the topic of several research analyst reports. Morgan Stanley initiated coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 price objective on the stock. JMP Securities reiterated a "market outperform" rating and set a $5.00 target price on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $8.00.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.